Omeros (OMER) Insider Hood Leroy Md Phd Buys 15,000 Shares
On June 18, 2026, insider Hood Leroy Md Phd purchased 15,000 shares of Omeros Corporation, signaling confidence in the company's future.
Reviewed by automated data checks against the source filing. How we make and check alerts
Hood Leroy Md Phd bought 15,000 shares of Omeros Corporation ($OMER) on June 18, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $OMER is up 4.3% after 1 week, down 6.3% after 1 month and up 57.6% to date (from the $10.28 close on Jun 18, 2026).
OMER
Omeros Corporation
Key Points
- Hood Leroy Md Phd bought 15,000 shares of Omeros Corporation, valued at approximately $154,950 based on the recent stock price of $10.33.
- Omeros Corporation is trading at $10.33, significantly below its 52-week high of $21.24, suggesting potential for recovery.
- Analysts maintain a buy rating for Omeros with a target price of $22.00, indicating positive sentiment about the company's growth.
Get $OMER trade alerts by text
We text you when insiders, Congress or big funds trade $OMER. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Omeros Corporation alert may contain errors. Disclosures
Insider Buying and Selling at Omeros Corporation
On June 18, 2026, insider Hood Leroy Md Phd bought 15,000 shares of Omeros Corporation (NasdaqGM: OMER). This purchase is valued at about $154,950 based on the stock's price of $10.33 at the time. This move adds to a wave of insider buying on the same day, reflecting a strong belief in the company's future.
A Surge of Insider Buying
This recent purchase is part of a broader trend at Omeros. Other insiders also bought shares on June 18, 2026. For instance, Thomas Cable, Peter Demopulos, Arnold Hanish, Thomas Bumol, Rajiv Shah, and Diana Perkinson each acquired 15,000 shares. These transactions show a collective confidence among Omeros insiders in the company's direction.
Analysts Set New Price Targets
Analysts are generally optimistic about Omeros. On October 14, 2026, Cantor Fitzgerald reiterated its Overweight rating with a price target of $22. Earlier, on September 22, 2026, they upgraded the stock to Overweight. HC Wainwright & Co. also maintains a Buy rating, but lowered its target from $40 to $33 on June 26, 2026. The overall consensus among analysts is a buy rating, with a mean target price of $27.5.
Stock Performance and Market Context
Omeros stock is currently trading at $10.33. This is well below its 52-week high of $21.24 and near its low of $6.24, suggesting it could be undervalued. The stock’s price has fluctuated significantly, which may attract investors looking for a rebound. With a P/E ratio of about 15.4, the stock presents a reasonable valuation compared to its growth potential.
Recent Earnings
In its latest earnings report, Omeros Corporation posted revenue of $38.4 million, with a net margin of about 3.25%. The next earnings date is set for November 12, 2026. Investors will be keen to see how the company continues to perform as it develops its clinical-stage products.
What Omeros Corporation Does
Omeros Corporation is a clinical-stage biopharmaceutical firm based in Seattle, Washington. It focuses on developing treatments for immunologic diseases, with key products in various stages of clinical trials. This insider buying could signal confidence in the company’s ongoing projects and future growth.
What’s Next for Omeros?
Investors will be watching closely for updates from Omeros, especially with the next earnings report coming on November 12, 2026. The recent insider transactions may indicate a strong belief in the company's potential as it continues its clinical trials. As a reminder, the recent insider buying reflects past activity and may not indicate current positions.
Related Filing Alerts
Source: Hood Leroy Md Phd's Form 4 filing on $OMER (Jun 18, 2026). Find the original filing: OMER Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts